NasdaqGS - Delayed Quote USD

Royalty Pharma plc (RPRX)

26.64 +0.02 (+0.08%)
At close: May 28 at 4:00 PM EDT
26.80 +0.16 (+0.60%)
After hours: May 28 at 7:58 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
2,238,561.00
2,354,554.00
2,237,215.00
2,289,463.00
2,122,353.00
--
Operating Expense
1,299,157.00
862,404.00
1,314,323.00
858,748.00
461,901.00
--
Operating Income
939,404.00
1,492,150.00
922,892.00
1,430,715.00
1,660,452.00
--
Net Non Operating Interest Income Expense
-121,463.00
-114,896.00
-109,626.00
-112,607.00
-128,680.00
--
Other Income Expense
368,785.00
322,834.00
-583,202.00
-76,907.00
170,182.00
--
Pretax Income
1,186,726.00
1,700,088.00
230,064.00
1,241,201.00
1,701,954.00
--
Net Income Common Stockholders
1,191,583.00
1,527,560.00
42,832.00
619,728.00
495,198.00
--
Diluted NI Available to Com Stockholders
1,191,583.00
1,527,560.00
42,832.00
619,728.00
495,198.00
--
Basic EPS
1.79
2.54
0.10
1.49
2.51
--
Diluted EPS
1.78
2.53
0.10
1.49
2.51
--
Basic Average Shares
448,353.75
447,601.00
437,963.00
414,794.00
388,135.00
--
Diluted Average Shares
600,457.00
602,900.00
437,972.00
414,802.00
388,135.00
--
Total Operating Income as Reported
939,404.00
1,492,150.00
307,065.00
1,430,715.00
1,595,399.00
--
Total Expenses
1,299,157.00
862,404.00
1,314,323.00
858,748.00
461,901.00
--
Net Income from Continuing & Discontinued Operation
798,857.00
1,134,834.00
42,832.00
619,728.00
975,040.00
--
Normalized Income
387,590.00
819,145.00
602,306.00
671,467.00
816,496.00
--
Interest Income
63,006.00
72,291.00
78,335.00
53,535.00
28,379.00
--
Interest Expense
184,469.00
187,187.00
187,961.00
166,142.00
157,059.00
--
Net Interest Income
-121,463.00
-114,896.00
-109,626.00
-112,607.00
-128,680.00
--
EBIT
1,371,195.00
1,887,275.00
418,025.00
1,407,343.00
1,859,013.00
--
EBITDA
1,371,195.00
1,887,275.00
423,695.00
1,430,339.00
1,882,071.00
--
Reconciled Depreciation
--
--
5,670.00
22,996.00
23,058.00
--
Net Income from Continuing Operation Net Minority Interest
798,857.00
1,134,834.00
42,832.00
619,728.00
975,040.00
--
Total Unusual Items Excluding Goodwill
411,267.00
315,689.00
-559,474.00
-51,739.00
158,544.00
--
Total Unusual Items
411,267.00
315,689.00
-559,474.00
-51,739.00
158,544.00
--
Normalized EBITDA
959,928.00
1,571,586.00
983,169.00
1,482,078.00
1,723,527.00
--
12/31/2019 - 6/16/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CYTK Cytokinetics, Incorporated
48.21
-0.19%
 
BBIO BridgeBio Pharma, Inc.
27.82
-0.43%
 
ROIV Roivant Sciences Ltd.
10.83
-1.37%
 
ARGX argenx SE
366.34
-0.20%
 
INCY Incyte Corporation
57.25
-0.10%
 
LEGN Legend Biotech Corporation
41.68
+0.65%
 
ALNY Alnylam Pharmaceuticals, Inc.
150.06
+1.56%
 
CLRB Cellectar Biosciences, Inc.
2.9600
-4.82%
 
GMAB Genmab A/S
28.01
+0.04%
 
ASND Ascendis Pharma A/S
127.33
-2.36%